Impaired Driving

2

Review clinical trials related to Impaired Driving. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Examining the Role of Tolerance on Dose-dependent Effects of Acute THC on Oculomotor and Cognitive Performance

The purpose of this research is to determine the extent to which oculomotor function accurately detects THC-impairment, if cannabis use experience impacts this detection threshold, and to examine how the oculomotor index corresponds to a measure of sustained attention. A double-blind, placebo-controlled, within-subjects crossover design will be used to examine the dose-effects of THC (0, 5mg, 30mg) on oculomotor performance tasks and a sustained attention task in frequent and infrequent cannabis users. Results from the study will advance the investigators' understanding of the effect of THC and cannabis use frequency on oculomotor function and sustained attention, and will directly inform the validity of the investigators' oculomotor platform for identifying acute THC- induced impairment in frequent and infrequent users.

Participants needed: 40
Trial details
Phase: Phase 1Age: 18-60Biological sex: AllType: InterventionalSponsor: Johns Hopkins UniversityUpdated: May 27, 2026Locations: 1
Eligibility criteria

Inclusion criteria: Healthy non-treatment seeking adults (age 18 to 60, N = 40)... [+2]

(1) meet DSM-V criteria for substance use disorders other than tobacco, cannabis... [+6]

Status: Not yet recruiting

Assessing the Effectiveness of Screening, Brief Intervention, and Referral to Treatment (SBIRT) With Personalized Feedback Intervention to Reduce Polysubstance Impaired Driving in Young Adults Aged 18-30

The current study is assessing the effects of receiving Screening, Brief Intervention and Referral to Treatment alone versus also receiving a brief online personalized intervention on impaired driving behaviors among Washington State young adults aged 18-30.

Participants needed: 600
Trial details
Age: 18-30Biological sex: AllType: InterventionalSponsor: University of WashingtonUpdated: Jan 27, 2026
Eligibility criteria

Aged 18-30 at enrollment [+6]

Not meeting eligibility criteria [+1]